Whitehawk Presents Preclinical Findings on Next-Gen ADCs at AACR 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy WHWK?
Source: PRnewswire
- Preclinical Research Findings: Whitehawk Therapeutics will present three preclinical research findings on antibody-drug conjugates (ADCs) at the 2026 American Association for Cancer Research Annual Meeting, providing comprehensive proof-of-concept for HWK-007, HWK-016, and HWK-206 aimed at improving cancer patient outcomes.
- High Efficacy Performance: The research indicates that Whitehawk's ADCs exhibit high potency with significant tumor regressions at low single-digit mg/kg doses, and in non-human primate studies, a highest non-severely toxic dose (HNSTD) of 60 mg/kg demonstrates excellent tolerability.
- Innovative Technology Application: The study utilizes Whitehawk's proprietary
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WHWK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WHWK
Wall Street analysts forecast WHWK stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.280
Low
7.00
Averages
7.00
High
7.00
Current: 3.280
Low
7.00
Averages
7.00
High
7.00
About WHWK
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Whitehawk Presents Preclinical Findings on Next-Gen ADCs at AACR 2026
- Preclinical Research Findings: Whitehawk Therapeutics will present three preclinical research findings on antibody-drug conjugates (ADCs) at the 2026 American Association for Cancer Research Annual Meeting, providing comprehensive proof-of-concept for HWK-007, HWK-016, and HWK-206 aimed at improving cancer patient outcomes.
- High Efficacy Performance: The research indicates that Whitehawk's ADCs exhibit high potency with significant tumor regressions at low single-digit mg/kg doses, and in non-human primate studies, a highest non-severely toxic dose (HNSTD) of 60 mg/kg demonstrates excellent tolerability.
- Innovative Technology Application: The study utilizes Whitehawk's proprietary
See More
Whitehawk Therapeutics Showcases Next-Gen ADCs at AACR 2026
- Preclinical Data Presentation: Whitehawk Therapeutics will present three preclinical abstracts at the 2026 American Association for Cancer Research Annual Meeting, showcasing comprehensive proof-of-concept for its ADC programs HWK-007, HWK-016, and HWK-206, aimed at improving cancer treatment outcomes.
- High Efficacy and Tolerability: These ADCs demonstrated high potency with tumor regressions in xenograft studies at low single-digit mg/kg doses, and in non-human primate studies, the highest non-severely toxic dose (HNSTD) reached 60 mg/kg, indicating excellent tolerability.
- Innovative Technology Utilization: Whitehawk's ADCs utilize its proprietary
See More
Whitehawk Therapeutics Reports Q4 Financial Results
- Financial Performance: Whitehawk Therapeutics reported a Q4 GAAP EPS of -$0.34, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $145.7 million, a significant increase from $47.2 million in 2024, reflecting substantial progress in financial management.
- Funding Outlook: The current cash reserves are anticipated to fund operations into 2028, providing financial security for future R&D and market expansion, thereby enhancing the company's long-term growth potential.
- Market Reaction Expectations: Despite the increase in cash reserves, the negative EPS may raise concerns about the company's future profitability, prompting investors to closely monitor subsequent strategic adjustments and financial performance.
See More
Whitehawk Therapeutics to Present at Oppenheimer 36th Annual Healthcare Conference
- Presentation Schedule: Dr. Dave Lennon, CEO of Whitehawk Therapeutics, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST, showcasing the company's latest advancements in oncology treatments.
- Webcast Availability: The presentation will be live-streamed on Whitehawk Therapeutics' investor relations website and will be available for replay for approximately 30 days post-event, ensuring that investors and the public can access key information in a timely manner.
- Company Background: Whitehawk Therapeutics is a clinical-stage oncology therapeutics company focused on leveraging advanced technologies to enhance antibody-drug conjugate (ADC) cancer treatments, aiming to provide effective solutions for patients with difficult-to-treat cancers.
- Portfolio Advantages: The company boasts an advanced three-asset ADC portfolio, licensed exclusively from WuXi Biologics under a global commercialization agreement, designed to overcome the limitations of first-generation products and deliver significant therapeutic impact for patients.
See More
Whitehawk Initiates Phase 1 Trial for HWK-007, Initial Data Expected Early 2027
- Trial Initiation: Whitehawk Therapeutics has received FDA clearance for its Phase 1 trial of HWK-007, which is now actively recruiting participants to evaluate its efficacy in lung and ovarian cancers, potentially offering new treatment options for patients.
- IND Submission: The company submitted an IND for HWK-016 to the FDA in December 2025, with plans to initiate Phase 1 trials this quarter targeting high MUC16-expressing ovarian and endometrial cancers, thereby expanding its therapeutic pipeline.
- Technological Edge: Both HWK-007 and HWK-016 leverage Whitehawk's advanced ADC technology platform, which combines a highly stable yet cleavable linker to enhance tumor targeting while minimizing off-target toxicity, aiming to improve treatment outcomes.
- Market Opportunity: PTK7 is the third most highly expressed tumor marker among clinically validated ADC targets, present in approximately 70% of tumors, positioning Whitehawk's new drugs to fill a significant market gap and address unmet medical needs.
See More
Whitehawk Initiates Phase 1 Trial for HWK-007, Initial Data Expected Early 2027
- Trial Launch: Whitehawk Therapeutics has announced the active recruitment for its Phase 1 trial of HWK-007, aimed at evaluating its efficacy in PTK7-expressing tumors such as lung and ovarian cancers, marking a significant advancement in the company's oncology drug development.
- IND Submission: The company submitted an IND for HWK-016 to the FDA in December 2025, with a Phase 1 trial expected to start this quarter focusing on high MUC16-expressing ovarian and endometrial cancers, further expanding its antibody-drug conjugate (ADC) pipeline.
- Platform Advantages: Whitehawk's ADC technology platform features a highly stable yet cleavable linker designed to maximize tumor targeting while minimizing off-target toxicity, which is expected to provide more effective treatment options for patients and enhance market competitiveness.
- Data Release Expectations: The company anticipates reporting initial clinical data for both HWK-007 and HWK-016 in early 2027, which will provide crucial validation for the efficacy of its ADC programs and potentially drive future market opportunities.
See More
Whitehawk Presents Preclinical Findings on Next-Gen ADCs at AACR 2026
- Preclinical Research Findings: Whitehawk Therapeutics will present three preclinical research findings on antibody-drug conjugates (ADCs) at the 2026 American Association for Cancer Research Annual Meeting, providing comprehensive proof-of-concept for HWK-007, HWK-016, and HWK-206 aimed at improving cancer patient outcomes.
- High Efficacy Performance: The research indicates that Whitehawk's ADCs exhibit high potency with significant tumor regressions at low single-digit mg/kg doses, and in non-human primate studies, a highest non-severely toxic dose (HNSTD) of 60 mg/kg demonstrates excellent tolerability.
- Innovative Technology Application: The study utilizes Whitehawk's proprietary
See More
Whitehawk Therapeutics Showcases Next-Gen ADCs at AACR 2026
- Preclinical Data Presentation: Whitehawk Therapeutics will present three preclinical abstracts at the 2026 American Association for Cancer Research Annual Meeting, showcasing comprehensive proof-of-concept for its ADC programs HWK-007, HWK-016, and HWK-206, aimed at improving cancer treatment outcomes.
- High Efficacy and Tolerability: These ADCs demonstrated high potency with tumor regressions in xenograft studies at low single-digit mg/kg doses, and in non-human primate studies, the highest non-severely toxic dose (HNSTD) reached 60 mg/kg, indicating excellent tolerability.
- Innovative Technology Utilization: Whitehawk's ADCs utilize its proprietary
See More
Whitehawk Therapeutics Reports Q4 Financial Results
- Financial Performance: Whitehawk Therapeutics reported a Q4 GAAP EPS of -$0.34, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $145.7 million, a significant increase from $47.2 million in 2024, reflecting substantial progress in financial management.
- Funding Outlook: The current cash reserves are anticipated to fund operations into 2028, providing financial security for future R&D and market expansion, thereby enhancing the company's long-term growth potential.
- Market Reaction Expectations: Despite the increase in cash reserves, the negative EPS may raise concerns about the company's future profitability, prompting investors to closely monitor subsequent strategic adjustments and financial performance.
See More
Whitehawk Therapeutics to Present at Oppenheimer 36th Annual Healthcare Conference
- Presentation Schedule: Dr. Dave Lennon, CEO of Whitehawk Therapeutics, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST, showcasing the company's latest advancements in oncology treatments.
- Webcast Availability: The presentation will be live-streamed on Whitehawk Therapeutics' investor relations website and will be available for replay for approximately 30 days post-event, ensuring that investors and the public can access key information in a timely manner.
- Company Background: Whitehawk Therapeutics is a clinical-stage oncology therapeutics company focused on leveraging advanced technologies to enhance antibody-drug conjugate (ADC) cancer treatments, aiming to provide effective solutions for patients with difficult-to-treat cancers.
- Portfolio Advantages: The company boasts an advanced three-asset ADC portfolio, licensed exclusively from WuXi Biologics under a global commercialization agreement, designed to overcome the limitations of first-generation products and deliver significant therapeutic impact for patients.
See More
Whitehawk Initiates Phase 1 Trial for HWK-007, Initial Data Expected Early 2027
- Trial Initiation: Whitehawk Therapeutics has received FDA clearance for its Phase 1 trial of HWK-007, which is now actively recruiting participants to evaluate its efficacy in lung and ovarian cancers, potentially offering new treatment options for patients.
- IND Submission: The company submitted an IND for HWK-016 to the FDA in December 2025, with plans to initiate Phase 1 trials this quarter targeting high MUC16-expressing ovarian and endometrial cancers, thereby expanding its therapeutic pipeline.
- Technological Edge: Both HWK-007 and HWK-016 leverage Whitehawk's advanced ADC technology platform, which combines a highly stable yet cleavable linker to enhance tumor targeting while minimizing off-target toxicity, aiming to improve treatment outcomes.
- Market Opportunity: PTK7 is the third most highly expressed tumor marker among clinically validated ADC targets, present in approximately 70% of tumors, positioning Whitehawk's new drugs to fill a significant market gap and address unmet medical needs.
See More
Whitehawk Initiates Phase 1 Trial for HWK-007, Initial Data Expected Early 2027
- Trial Launch: Whitehawk Therapeutics has announced the active recruitment for its Phase 1 trial of HWK-007, aimed at evaluating its efficacy in PTK7-expressing tumors such as lung and ovarian cancers, marking a significant advancement in the company's oncology drug development.
- IND Submission: The company submitted an IND for HWK-016 to the FDA in December 2025, with a Phase 1 trial expected to start this quarter focusing on high MUC16-expressing ovarian and endometrial cancers, further expanding its antibody-drug conjugate (ADC) pipeline.
- Platform Advantages: Whitehawk's ADC technology platform features a highly stable yet cleavable linker designed to maximize tumor targeting while minimizing off-target toxicity, which is expected to provide more effective treatment options for patients and enhance market competitiveness.
- Data Release Expectations: The company anticipates reporting initial clinical data for both HWK-007 and HWK-016 in early 2027, which will provide crucial validation for the efficacy of its ADC programs and potentially drive future market opportunities.
See More
